This is a knockout-validated antibody summary, based on the publication "BRCC3 Promotes Tumorigenesis of Bladder Cancer by Activating the NF-κB Signaling Pathway Through Targeting TRAF2", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

[enlarge]

Figure 1. BRCC3-deficient cells were identified via Western blotting assays. From [1].

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: BRCC36

Catalog number: 18215

Summary: Rabbit monoclonal antibody against a synthetic peptide corresponding to residues surrounding His251 of human BRCC36 isoform 2 protein. Reacts with human, mouse, rat, and monkey. Suitable for western blot and immunoprecipitation.

Western blot

WT and BRCC3-KO T24 cells.

TBST (containing 5% non-fat dry milk) for 60 min at room temperature.

1:1,000 dilution overnight at 4°C.

HRP-conjugated secondary antibodies at 37°C for 2 h at room temperature.

WesternBright ECL HRP substrate (Advansta).